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Abstract 
Background: Endometriosis, pro‑inflammatory and invasive benign disease estrogen dependent, abnormally 
express in endometria the enzyme P450Arom, positively regulated by steroid factor‑1 (SF‑1). Our objective was to 
study the nuclear protein contents of upstream stimulating factor 2 (USF2a and USF2b), a positive regulator of SF‑1, 
throughout the menstrual cycle in eutopic endometria from women with and without (control) endometriosis and 
the involvement of nuclear estrogen receptors (ER) and G‑coupled protein estrogen receptor (GPER)‑1.
Results: Upstream stimulating factor 2 protein contents were higher in mid (USF2b) and late (USF2a and USF2b) 
secretory phase in eutopic endometria from endometriosis than control (p < 0.05). In isolated control epithelial cells 
incubated with E2 and PGE2, to resemble the endometriosis condition, the data showed: (a) significant increase of 
USF2a and USF2b nuclear protein contents when treated with E2, PPT (specific agonist for ERα) or G1 (specific agonist 
for GPER1); (b) no increase in USF2 binding to SF‑1 E‑Box/DNA consensus sequence in E2‑treated cells; (c) USF2 vari‑
ants protein contents were not modified by PGE2; (d) SF‑1 nuclear protein content was significantly higher than basal 
when treated with PGE2, E2 or G1, stimulation unaffected by ICI (nuclear ER antagonist); and (e) increased (p < 0.05) 
cytosolic protein contents of P450Arom when treated with PGE2, E2, PPT or G1 compared to basal, effect that was addi‑
tive with E2 + PGE2 together. Nevertheless, in endometriosis cells, the high USF2, SF‑1 and P450Arom protein contents 
in basal condition were unmodified.
Conclusion: These data strongly suggest that USF2 variants and P450Arom are regulated by E2 through ERα and 
GPER1, whereas SF‑1 through GPER1, visualized by the response of the cells obtained from control endometria, being 
unaffected the endogenously stimulated cells from endometriosis origin. The lack of E2 stimulation on USF2/SF‑1 
E‑Box/DNA‑sequence binding and the absence of PGE2 effect on USF2 variants opposite to the strong induction 
that they exert on SF1 and P450 proteins suggest different mechanisms and indirect regulations. The sustained USF2 
variants protein expression during the secretory phase in eutopic endometria from women with endometriosis may 
participate in the pathophysiology of this disease strongly associated with infertility and its characteristic endometrial 
invasion to ectopic sites in the pelvic cavity.
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Background
Endometriosis is an estrogen-dependent gynecologic dis-
ease, characterized by the presence and growth of endo-
metrium outside the uterine cavity. This pathology affects 
about 10 % of reproductive-age women and is associated 
with infertility, chronic pelvic pain, dysmenorrhea, and 
dyspareunia [1–4]. The etiology of this disease remains 
incompletely understood [5]. Retrograde menstruation 
with viable endometrial fragments has been advocated 
as one of the mechanisms by which the endometrium 
reaches the peritoneal cavity [6]. However, this theory fails 
to explain why only a select group of women experiencing 
retrograde menstruation develops endometriosis [7].
Endometrial estrogenic microenvironment has been 
shown to be an important factor in the pathophysiology 
of endometriosis by abnormal expression of enzymes 
involved in estrogen synthesis and degradation [8, 9]. The 
activation of CYP19A1 gene induces P450Arom expres-
sion, the rate-limiting enzyme in conversion of androgens 
to estrogens. Normally, steroid factor-1 (SF-1) positively 
regulates the CYP19A1 gene in the ovary, though not in 
the normal endometrium. Nevertheless, SF-1, expressed 
in eutopic and ectopic endometria from women with 
endometriosis, aberrantly activates CYP19A1 and the 
expression of P450Arom in stroma [10–12] or gland [13, 
14] in these tissues as has been extensively described 
favoring this estrogenic microenvironment in this 
disease.
SF-1 gene is recognized in a region called E-box by 
upstream stimulatory factor (USF), the ubiquitous tran-
scription factor involved on embryonic development, 
fertility, stress, growth and lipid and carbohydrate metab-
olisms [15, 16]. Although two types of USF, USF1 and 
USF2, have been reported, it is USF2 that shows the high-
est binding activity on SF-1 promoter and its knockdown 
results in down-regulation of SF-1 and also of its target 
gene CYP19A1 in ectopic endometrium from endome-
triosis women [17]. Two variants of USF2, produced by 
alternative splicing, have been reported, the bigger USF2a 
(44 kDa) and the smaller USF2b (38 kDa) by the loss of 67 
internal amino acid in the N-terminal domain [15, 18].
Estradiol (E2) acts through the classic nuclear estrogen 
receptors (ER), ERα and ERβ, both strictly regulated by 
the ovarian steroid hormones during the menstrual cycle, 
with a predominance of ERα over ERβ in the normal 
endometrium and reducing their expression during the 
secretory phase [19–22]. In eutopic endometrium from 
women with endometriosis, although each ER isoforms 
are increased, the ERα/ERβ ratio is decreased affecting 
the normal actions of E2 in this tissue [23, 24]. In addi-
tion, a membrane receptor called G-protein estrogen 
receptor 1 (GPER1) presents high affinity for E2 in vitro 
[25, 26] and has been described as potentially responsible 
of early and non genomic responses of estrogen in several 
cell lines and tissues including the endometrium [27–29].
The aberrant expression of CYP19A1 and SF-1 genes in 
eutopic and ectopic endometria of women with endome-
triosis led us to study USF2 variants protein contents in 
human endometrium throughout the menstrual cycle and 
the effect of estrogenic and proinflammatory environments 
in epithelial cells of eutopic endometrium from women with 
and without endometriosis. The involvement of nuclear 
ERα, ERβ or GPER1 in the E2 action on USF2 variants, SF-1 
and P450Arom protein expression was also evaluated.
Results
USF2 protein contents in endometrium throughout the 
menstrual cycle
The protein content of both USF2a and USF2b variants 
were detected by immunoblot (Fig.  1) in endometrium 
from women with endometriosis and controls. No inter-
actions between USF2 protein studies and subject age 
was found by ANCOVA.
Two protein bands (44 and 38 kDa), corresponding to 
USF2a and USF2b variants, respectively, were found in 
the nuclear compartment of control and endometrio-
sis endometria (Fig.  1). In control endometria, nuclear 
USF2a protein content decreased in early and late 
secretory phases (37 and 57 %, respectively, p < 0.05) as 
compared to the proliferative phase. On the other hand, 
in endometriosis, USF2a contents were lower during the 
late secretory as compared to the mid secretory phase, 
although higher than late control endometria (Fig. 1a).
During mid and late secretory phases, USF2b (38 kDa) 
nuclear protein content significantly decreased (39 and 
34 %, respectively) as compared to proliferative phase in 
control endometria, instead it was observed an increase 
in endometriosis endometria during the same stages of 
the menstrual cycle, being higher 100 and 155 %, respec-
tively, than control (Fig. 1b).
Stimulatory effect of E2 and PGE2 on USF2, SF‑1 
and P450Arom protein contents
In endometriosis epithelial cells, nuclear protein contents 
of USF2a and USF2b were significantly higher in basal con-
dition than control cells. Nevertheless, only in control cells, 
E2 increased USF2a (103 %) and USF2b (91 %) nuclear pro-
tein contents, effect also partially blocked by the presence 
of ICI (Fig.  2a, b). Nuclear protein homogenate obtained 
from control and endometriosis epithelial cells bound to 
target E-Box motif, complexes displaced by cold probe. 
The previous incubation of the nuclear protein homogen-
ates with USF2 antibody shifted partially the protein/E-Box 
complex in basal or E2-treated conditions (Fig. 2c).
We observed a null effect on USF2a and USF2b nuclear 
protein contents of 10−8 mol/L PGE2, in the presence or 
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absence of 10−8 mol/L E2 in isolated epithelial cells from 
both control and endometriosis endometria (Fig. 2a, b).
Epithelial cells obtained from endometriosis endome-
tria had high SF-1 protein expression in basal condition, 
which were resistant to E2 and PGE2 (Fig.  3a). On the 
contrary, in control epithelial cells, the SF-1 protein con-
tent was strongly increased by E2 (126  %) as compared 
to basal, effect not modified by the presence of ICI. The 
presence of PGE2 also increased the content of SF-1 pro-
tein (154 %) as compared to basal, although no additive 
or synergistic effects were observed when E2 and PGE2 
were added together (Fig. 3a).
Similarly to SF-1 protein results, the cytosolic protein 
content of P450Arom was strongly high in epithelial cells 
from endometriosis endometria in basal condition, and 
also resistant to E2 and PGE2 presences (Fig. 3b). In con-
trol epithelial cells, P450Arom protein content was signifi-
cantly increased by E2 (292 %), effect partially blocked by 
ICI pre-treatment. PGE2 increased (258  %) the protein 
content of P450Arom and the presence of both, E2 and 
Fig. 1 USF2a (a) and USF2b (b) nuclear protein contents in eutopic endometria throughout the menstrual cycle. Endometria were obtained 
from seven women without (control) and seven women with endometriosis in each stage of the menstrual cycle. Representative immunoblots 
are shown. Data were normalized with TFIIB protein contents. Results are the mean ± SEM. *p < 0.05 vs. control; #p < 0.05 vs. proliferative phase; 
ºp < 0.05 vs. late secretory phase
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Fig. 2 E2 and PGE2 effect on USF2 variants protein contents and SF‑1 E‑Box DNA binding. USF2a (a) and USF2b (b) nuclear protein contents of 
endometrial epithelial cells (EEC) from women with and without (control) endometriosis treated with E2 (10
−8 mol/L) and/or PGE2 (10
−8 mol/L) in 
the presence or absence of ICI (10−6 mol/L; 30 min previously added); all data were normalized with TFIIB. Representative immunoblot is shown. 
Results are the mean ± SEM of EEC obtained from 7 control women and 7 women with endometriosis. c Representative SF‑1 E‑Box DNA shift assay 
from 3 gels. Lane 1 free probe; lanes 2–5 nuclear protein from control EEC (2 basal condition; 3 E2 treated; 4 basal + anti USF2 antibody; 5 E2 + anti 
USF2 antibody); lanes 6 and 7: nuclear protein from endometriosis endometrial epithelial cells (6 basal condition; 7 basal + anti USF2 antibody), 
and lane 8 basal condition + cold competitor. Protein procurements and assays are described in “Methods”. *p < 0.05 control; #p < 0.05 vs. baseline; 
ºp < 0.05 vs. E2
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PGE2, shows an additive effect (525  %) on the protein 
content (Fig. 3b).
Specific agonists of estrogen receptors involved on USF2, 
SF‑1 and P450Arom protein content by E2 stimulation
Taking into account that cells obtained from endometrio-
sis women are highly endogenously stimulated, control 
epithelial cells were used for the following experiments to 
assess the ER isoform involvement. For that, control cells 
were incubated with specific agonists for ERα (PPT), ERβ 
(DPN) and GPER1 (G1).
These cells responded to PPT at 10−7 mol/L and G1 at 
10−6 mol/L, increasing the protein content of USF2a by 
153 and 164 % and USF2b by 169 and 109 %, respectively 
Fig. 3 E2 and PGE2 effect on SF‑1 and P450Arom protein levels in endometrial epithelial cells. Isolated endometrial epithelial cells (EEC) obtained 
from 4 to 6 women with or without (control) endometriosis were treated for 24 h with E2 (10
−8 mol/L) and/or PGE2 (10
−8 mol/L) in the presence and 
absence of ICI (10−6 mol/L; 30 min previously added). Representative immunoblots are shown. Data for SF‑1 (nuclear homogenates) were normal‑
ized with TFIIB (a) and for P450Arom (cytosol homogenates) with GAPDH (b). Results are the mean ± SEM. *p < 0.05 vs.control; #p < 0.05 vs. basal, 
ºp < 0.05 vs. one treatment
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(p < 0.05). The stimulatory effect of PPT was blocked by 
the presence of ICI. Paradoxically, ICI alone increased 
both USF2 variants. No significant effect was observed 
with DPN (Fig. 4a, b).
Only G1 increased SF-1 nuclear protein content by 
250 % at 10−6 mol/L in the control cells (Fig. 5a). Similarly 
to SF-1, P450Arom cytosolic protein content was increased 
in a dose-dependent manner by G1 (242  %) and also by 
PPT (232 %) as compared to basal condition (Fig. 5b).
Discussion
To our knowledge, this is the first report on human 
endometrial USF2a and USF2b protein co-expression 
throughout the menstrual cycle, and their positive regu-
lation by E2 through ERα and GPER1.
The reduced nuclear protein content of USF2 vari-
ants during the late secretory phase in control endo-
metria is consistent with the decreased plasma E2 and 
progesterone levels during this period of the menstrual 
cycle. In contrast, eutopic endometria from endometrio-
sis patients exhibited high USF2 variants protein con-
tents during this stage coincidently with the estrogenic 
microenvironment described in the eutopic and ectopic 
endometria of these patients [10, 13, 14, 30–32]. On the 
other hand, the opposite expression of USF2a and USF2b 
found in control endometria during the mid secretory 
phase, when the embryo implantation occurs, was not 
observed in eutopic endometria from endometriosis 
women, which may contribute to the infertility associ-
ated to this pathology. The different expression patterns 
Fig. 4 Dose‑response curves of specific agonists on USF2a (a) and USF2b (b) nuclear protein content. Endometrial epithelial cells obtained from 4 
control women were treated for 24 h with E2 (10
−8 mol/L), PPT (10−9 to 10−7 mol/L), DPN (10−9 to 10−7 mol/L), and G1 (10−8 to 10−6 mol/L) in the 
presence or absence of ICI (10−6 mol/L; 40 min previously added). Representative immunoblot is shown. Data were normalized with TFIIB. Results 
are the mean ± SEM of EEC obtained from at least 4 control women. *p < 0.05 vs. basal; #p < 0.05 vs. agonist
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of endometrial USF2 variants between women with and 
without endometriosis throughout the menstrual cycle 
add new molecules to those abnormally expressed in this 
tissue as has been widely reported [33–36]
We observed a strong E2-stimulatory effect on USF2 
variants nuclear protein contents in epithelial cells from 
control endometria. These findings are supported by the 
epithelial cells response to ICI, an antagonist of ERα and 
ERβ, which partially blocked those effects induced by 
E2, but completely blocked those induced by PPT (spe-
cific agonist of ERα) and acting as agonist for GPER1, 
unaffected those effects induced by G1 (specific agonist 
Fig. 5 Dose‑response curves of specific agonists on SF‑1 (a) and P450Arom (b) protein content. Endometrial epithelial cells obtained from 4 control 
women were treated with E2 (10
−8 mol/L), PPT (10−9 to 10−7 mol/L), DPN (10−9 to 10−7 mol/L), and G1 (10−8 to 10−6 mol/L). Representative immu‑
noblots are shown. Data for SF‑1 (nuclear homogenates) were normalized with TFIIB and for P450Arom (cytosol homogenates) with GAPDH. Results 
are the mean ± SEM. *p < 0.05 vs. basal
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of GPER1), confirming the dual action of ICI on estro-
gen receptors [37]. These data suggest that this process 
is under ovarian steroid regulation through the classic 
nuclear ERα and also GPER1. Interestingly, positive regu-
lation of the ERα expression by USF2 has been reported 
in sheep uterine arteries [32, 38] showing a complex rela-
tionship between both transcription factors. The action 
of E2 through GPER1 not only may be involved on the 
USF2 protein synthesis or viability, but also on the USF2 
activation through several pathways described for GPER1 
[25, 39–41]. This aspect is of high relevance consider-
ing the important role, beside the cell-specificity, that 
specific phosphorylation plays on the activation of USF 
protein that modifies its function from tumor suppressor 
in prostate cancer to tumor promoter in lung cancer and 
thyroid cancer as recently Horbach et  al. reported [15, 
42].
Our first hypothesis was that the strong increase of 
USF2 induced by E2 might stimulate the SF-1 transcrip-
tion activating the E-box motif, which in turn may induce 
Cyp19A1 gene increasing the key enzyme P450Arom. 
However, the discordance between the high USF2 pro-
tein expression and the weak binding observed on SF-1 
E-Box DNA consensus studies suggests a partial effect 
of USF2 on SF-1 gene promoter in cell treated with E2. 
Nevertheless, more studies are needed to confirm or to 
discard this pathway. Furthermore, the proinflammatory 
environment, generated by PGE2, was unable to modify 
USF2 variants protein, although induced a strong stimu-
lation on SF-1 and P450Arom protein contents, indicating 
different regulations.
The up-regulation of P450Arom by PGE2 through 
cAMP/CREB signaling pathway was previously reported 
[1, 11, 12, 43]. The additive effect of E2 and PGE2 on 
P450Arom protein contents indicates different activation 
mechanisms. Similar additive effect we reported pre-
viously in isolated control epithelial cells treated with 
peritoneal fluid from endometriosis women (PF-E) and 
Bu2cAMP [44] mimicking the conditions of the endo-
metriotic lesions. In our control epithelial cell model, 
P450Arom stimulation by E2 was through ERα and GPER1, 
but not through ERβ as it was previously proposed [1, 45] 
probably by the use of isolated control epithelial cells and 
not endometriotic stromal cells. It is known the impor-
tant role of SF-1 on steroid hormone biosynthesis, and 
also on development, differentiation, and function of the 
endocrine tissues [46]. The non-classic receptor GPER1 
mediating the E2 stimulatory action on SF-1 protein con-
tent as shown by our G1 data, is in agreement with SF-1 
activation and endometrial cell proliferation through the 
PI3K and MAPK pathways activated in several cell lines 
transfected with GPER1 [39, 40]. However, cAMP path-
way cannot be ruled out according to similar response to 
(Bu)2cAMP of control or SF-1-transfected endometrial 
epithelial cells as we previously reported [44].
In the present study, control epithelial cells were sen-
sitive to E2 and/or PGE2 treatments, mimicking the 
estrogenic and pro-inflammatory microenvironment 
described in endometriosis, inducing abnormal mol-
ecule expression similarly to endometria from women 
with endometriosis as has been widely reported by sev-
eral authors including our own group [14, 33–36, 47]. 
Very little information are regarding USF2, and even less 
about USF2 variants. Our data of sustained USF2 protein 
expression during the secretory phase in eutopic endo-
metria of women with endometriosis, an invasive estro-
gen-dependent disease, and the fact that the USF2 action 
is cell specific and may change its function from tumor 
suppressor to tumor promoter with invasive character-
istics [15, 42], suggest that USF2 may be involved in the 
pathophysiology of the endometriosis.
Conclusions
To our knowledge, this is the first report that shows USF2 
variants protein expression patterns in human normal 
and pathologic endometria during the menstrual cycle 
and its E2 stimulation mediated by ERα and GPER1 vis-
ualized by the response of cells obtained from control 
endometria, being unaffected the endogenously stimu-
lated cells from endometriosis origin. The lack of E2 stim-
ulation on USF2/SF-1 E-Box/DNA-sequence binding and 
the absence of PGE2 effect on USF2 variants opposite to 
the strong induction that they exert on SF1 and P450 pro-
teins suggest different mechanisms and regulations. The 
sustained USF2 protein expression during the secretory 
phase in eutopic endometria of women with endometrio-
sis may participate in the pathophysiology of this disease 
strongly associated with infertility and its characteristic 
endometrial invasion to ectopic sites in the pelvic cavity.
Methods
Subjects
Eutopic endometrium was obtained from 37 women 
undergoing diagnostic laparoscopy for endometriosis 
associated with pain and/or infertility (endometriosis 
group), and 49 women without endometriosis undergo-
ing laparoscopy for tubal ligation or hysterectomy for a 
benign non-endometrial gynecologic condition (control 
group) in the Clinical Hospital San Borja-Arriarán. The 
age of these women was 33.9 ± 5.6 years for the endome-
triosis group and 36.7 ± 6.5 years for the control group 
(p < 0.05). Both groups of women had abstained from any 
hormonal treatment for at least 3  months prior to sur-
gery. Endometrial biopsies were obtained during surgery 
with Cornier pipelle suction curettage from the corpus 
of the uterus, kept in cold sterile phosphate buffer saline 
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(PBS), and transported to the laboratory at 4  °C. One 
piece of the tissue was fixed in formalin for histological 
evaluation, others pieces were frozen for protein studies 
or used for endometrial epithelial cells isolation.
The endometriosis grade was 49 % minimal-mild (score 
1–15 points) and 51  % moderate-severe (score ≥16 
points) according to American Society of Reproductive 
Medicine criteria [48]. Endometriosis was diagnosed 
during surgery by visual evaluation by an experimented 
surgeon in each patient. This study was approved by the 
ethical committees of Faculty of Medicine of University 
of Chile and Metropolitan Central Health Service of 
Chile; each patient signed a written informed consent 
before surgery.
Endometrial samples were dated according to Noyes 
criteria [49] and classified as proliferative (days 6–14; 
12 control and 9 endometriosis samples) phase or early 
(days 15–18; 12 control and 10 endometriosis), mid (days 
19–23; 12 control and 10 endometriosis), and late secre-
tory phase (days 24–28; 13 control and 8 endometriosis).
Cell culture
Secretory endometrium was washed in PBS, minced, and 
digested according to previous indication [50]. The glands 
were separated and cultured according to previous indi-
cation [44, 50] and after the first or second passage, the 
cells were reseeded in duplicate protein studies until sub-
confluence. Then, the cells were incubated in fetal bovine 
serum-free medium (defined-medium) for 24  h, and 
treated for another 24  h in fresh defined-medium with-
out (basal) or with prostaglandin E2 (PGE2, 10−8  mol/L; 
Sigma), or E2 (10−8 mol/L; Sigma). Increasing concentra-
tions of Propylpyrazole-triol (PPT, 10−9 to 10−7  mol/L, 
Tocris  Bioscience, Bristol, UK) and Diarylpropionitrile 
(DPN, 10−9 to 10−7 mol/L, Tocris), specific agonists of ERα 
and ERβ, respectively, or G1 (10−8 to 10−6 mol/L, Merck 
KGaA, Darmstadt, Germany) specific agonist of GPER1, 
were also added to cell cultures for 24 h in the presence or 
absence of ICI-182,780 (10−6 mol/L, ERα and ERβ antago-
nist; Tocris) added 40 min before of ER agonists.
Protein homogenate preparation
Cytosolic and nuclear proteins from endometrial pieces 
and epithelial cells were obtained as previously reported 
[47]. The protein concentration was determined using 
the Bradford Assay reagent (BioRad, Hercules, CA, USA).
Thirty μg of cytosolic and nuclear proteins were dena-
tured, resolved in 10 % PAGE-SDS, and electrotransferred 
into nitrocellulose membranes (BioRad) as previously 
indicated [44, 50]. After blocking with 5  % BSA, the 
membranes were incubated overnight at 4  °C with pri-
mary antibodies against USF2 (polyclonal, 1:800; Abcam 
Inc, Cambridge, MA, USA), SF-1 (polyclonal, 1:800; ABR 
Affinity BioReagents, Golden, CO., USA), P450Arom 
(monoclonal; 1:600; Serotec, Oxford, UK), TFIIB (mon-
oclonal, 1:500; BD Biosciences, MD, USA), or GAPDH 
(polyclonal; 1:5000; Abcam). The images were captured 
with Discovery10gD (Ultralum, Claremont, CA, USA) 
using UltraQuant 6.0.0.344 software, analyzed with 
CarestreamMI5.0.6.20 software (Carestream Health, 
Inc., Rochester, NY, USA). The results were normalized 
with GAPDH or TFIIB analysis for cytosolic or nuclear 
extracts, respectively.
SF‑1 E‑Box DNA shift assay
The assay was performed using LightShift Chemilu-
minescent EMSA kit (Thermo Scientific, Rockford, IL, 
USA). Briefly, 5 µg nuclear proteins obtained as described 
above were incubated during 20  min at room tempera-
ture in a reaction mix which included 20 fmol biotin end-
labeled oligonucleotides that represented the SF-1 gene 
promoter containing the E-box (Integrated DNA Tech-
nologies, Inc., Coralville, IO, USA) following the manu-
facturer’s indications and as described Utsunomiya et al. 
[17] For supershift study, nuclear proteins were previ-
ously incubated with 1 µg USF2 antibody (Abcam) during 
2 h at 4 °C. The samples were resolved in non denaturing 
4  % polyacrylamide gel, electrotransferred to biodyne-
B membrane (Pall Corporation, Port Washington, NY, 
USA), which was UV-light crosslinked (UVP HL-2000 
HybriLinker, Cambridge, UK), blocked and the label 
detected following the manufacturer’s indications (Ther-
mos). The images were captured with Discovery10gD 
using UltraQuant 6.0.0.344 software.
Statistical analysis
Results are expressed as mean  ±  SEM. Kolmogorov–
Smirnov test was used to evaluate normal distribution. 
When non-parametric distribution was present Mann–
Whitney or Kruskal–Wallis tests were used, followed by a 
Dunn test. Means were expressed as percent of increase. 
Analysis of covariance (ANCOVA) was employed to 
test statistical interaction with co-variables like age and 
phases of the menstrual cycle.
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